ORPHA:730396
Invasive meningococcal disease
Also known as: IMD
Publications
3,026
Trials
3
Interventional, condition-specific
Researchers
1,189
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,026 matched papers (1,849 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,026
3,026 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,026 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,849 in the last 10 years · low confidence
Phrase hits: 3,026 · MeSH hits: 0
Who's working on it?
1,189
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Borrow R16 papers · 2026
UK Health Security Agency, Meningococcal Reference Unit, Manchester, UK. Electronic address: ray.borrow@ukhsa.gov.uk.
Papers in Europe PMC - 02Clark SA11 papers · 2026
UK Health Security Agency, Meningococcal Reference Unit, Manchester, UK.
Papers in Europe PMC - 03Lucidarme J11 papers · 2026
UK Health Security Agency, Meningococcal Reference Unit, Manchester, UK.
Papers in Europe PMC - 04
- 05Ladhani SN10 papers · 2026
UK Health Security Agency, Immunisation and Vaccine Preventable Diseases Division, London, UK.
Papers in Europe PMC - 06Campbell H8 papers · 2026
Immunisation Department, UK Health Security Agency (UKHSA), London, UK.
Papers in Europe PMC - 07Dinleyici EC7 papers · 2026
Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkiye.
Papers in Europe PMC - 08Herrera-Restrepo O7 papers · 2026
US Health Economics & Outcomes Research, GSK, Philadelphia, PA, USA.
Papers in Europe PMC - 09Findlow J6 papers · 2026
Pfizer Limited, Walton Oaks, Dorking Rd., Tadworth, KT20 7NS, UK.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 11 September 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
low confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 10 · after dedupe 10 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 10 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (10)
- isrctn·ISRCTN11952463·No longer recruiting·What’s the STORY: serum testing of representative youngsters including SARS-CoV-2 (COVID-19), diphtheria and meningitis C
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10901628·No longer recruiting·Portugal meningococcal B vaccine (menB) effectiveness study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16774163·No longer recruiting·Meningococcal B Booster Vaccine in Young People
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN75858406·No longer recruiting·Be on the TEAM: Teenagers Against Meningitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72009783·No longer recruiting·Understanding meningococcal carriage and disease in healthy teenagers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18766300·No longer recruiting·Multiboost - MCC plus pertussis booster in adolescents
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84763401·No longer recruiting·Responses to booster vaccinations in UK toddlers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57878347·No longer recruiting·A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vaccine booster given at 12 months of age to healthy children who have received the 13-valent pneumococcal conjugate vaccine at 2 and 4 months of age
skipped — LLM skipped (--skip-llm)
- ctis·2024-519549-31-00·Cancelled·A Phase 3b, open-label, multi-center study to assess the immune response and safety of the meningococcal group B vaccine rMenB+OMV NZ when administered to healthy participants aged 10 to 20 years old, who were primed during the first 2 years of life
skipped — LLM skipped (--skip-llm)
- ctis·2024-513640-29-00·Expired·Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in the elderly population
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Invasive meningococcal disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Invasive meningococcal disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Invasive meningococcal disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: IMD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-27T21:35:37.593Z